Abstract A165: Restrictive eligibility criteria impacts racial/ethnic enrollment in oncology therapeutic clinical trials: Findings from a large urban California institute

Abstract Background: To increase the number of people eligible for oncology clinical trials (CT) and improve their generalizability, ASCO and Friends of Cancer Research published recommendations in 2017 to broaden the CT eligibility criteria. NCI used these recommendations as the basis for the Experimental Therapeutics Clinical Trial Network protocols. The broadened CT criteria includes people with stable brain metastases, infectious disease (HIV and hepatitis B 75th percentile) vs. standard (≤75th) CTs. Using the NIH underrepresented minority population, we classified our outcome as minority (Hispanic/Black/American Indian/Alaska Native/Native Hawaiian/Pacific Islander) vs non-minority. We used multivariable mixed-effects logistic regression adjusting for sex, age, trial completed pre- vs. post-ASCO 2025 Sep 18-21; Baltimore, MD. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2025;34(9 Suppl):Abstract nr A165.